• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

卫生技术评估在中国决策制定中的应用：进展、挑战与可持续性。

Health technology assessment to inform decision making in China: progress, challenges, and sustainability.

机构信息

School of Public Health, Fudan University, Shanghai 200032, P R China

National Health Commission Key Laboratory of Health Technology Assessment, Fudan University.

出版信息

BMJ. 2023 Jun 15;381:e068910. doi: 10.1136/bmj-2021-068910.

DOI:10.1136/bmj-2021-068910
PMID:37321607
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10266481/
Abstract

examine China’s health technology assessment system and suggest how it can be strengthened

摘要

研究中国的卫生技术评估体系并提出如何加强该体系的建议

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecd3/10266481/c982b2ee0943/chey068910.f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecd3/10266481/c982b2ee0943/chey068910.f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecd3/10266481/c982b2ee0943/chey068910.f1.jpg

相似文献

1
Health technology assessment to inform decision making in China: progress, challenges, and sustainability.卫生技术评估在中国决策制定中的应用：进展、挑战与可持续性。
BMJ. 2023 Jun 15;381:e068910. doi: 10.1136/bmj-2021-068910.
2
Development of health technology assessment in China: New challenges.中国卫生技术评估的发展：新挑战。
Biosci Trends. 2018;12(2):102-108. doi: 10.5582/bst.2018.01038.
3
Use of health technology assessment in drug reimbursement decisions in China.中国药品报销决策中的卫生技术评估使用。
BMJ. 2023 Jun 15;381:e068915. doi: 10.1136/bmj-2021-068915.
4
Physician-patient shared decision making, patient satisfaction, and adoption of new health technology in China.医患共同决策、患者满意度和新医疗技术在中国的采用。
Int J Technol Assess Health Care. 2020 Oct;36(5):518-524. doi: 10.1017/S0266462320000719. Epub 2020 Oct 2.
5
Lessons from the sustainability movement: toward an integrative decision-making framework for nanotechnology.可持续发展运动的经验教训：迈向纳米技术综合决策框架
J Law Med Ethics. 2006 Winter;34(4):682-8. doi: 10.1111/j.1748-720X.2006.00087.x.
6
Multi-criteria decision analysis for health technology assessment in Canada: insights from an expert panel discussion.加拿大卫生技术评估中的多准则决策分析：专家小组讨论的观点。
Expert Rev Pharmacoecon Outcomes Res. 2015 Feb;15(1):13-9. doi: 10.1586/14737167.2015.965155. Epub 2014 Sep 30.
7
Using health technology assessment to support evidence-based decision-making in Canada: an academic perspective.利用健康技术评估支持加拿大循证决策：学术视角。
Expert Rev Pharmacoecon Outcomes Res. 2011 Oct;11(5):513-21. doi: 10.1586/erp.11.60.
8
Public preferences for engagement in Health Technology Assessment decision-making: protocol of a mixed methods study.公众参与卫生技术评估决策的偏好：一项混合方法研究的方案
BMC Med Inform Decis Mak. 2015 Jul 14;15:52. doi: 10.1186/s12911-015-0176-0.
9
Deliberative processes in decision making informed by health technology assessment in Latin America.拉丁美洲卫生技术评估决策中的审议过程。
Int J Technol Assess Health Care. 2022 Dec 16;38(1):e86. doi: 10.1017/S0266462322003294.
10
Defining the Value of Health Technologies in Latin America: Developments in Value Frameworks to Inform the Allocation of Healthcare Resources.定义拉丁美洲卫生技术的价值：用于指导医疗资源配置的价值框架的发展。
Int J Technol Assess Health Care. 2019 Jan;35(1):64-68. doi: 10.1017/S0266462319000072.

引用本文的文献

1
Assessing the development of health technology assessment in Iran: a policy analysis using Kingdon's Multiple streams framework: a qualitative study.评估伊朗卫生技术评估的发展：一项使用金登多源流框架的政策分析：一项定性研究。
BMC Public Health. 2025 Jan 20;25(1):226. doi: 10.1186/s12889-025-21465-5.
2
Developing mapping algorithms to predict EQ-5D health utility values from Bath Ankylosing Spondylitis Disease Activity Index and Bath Ankylosing Spondylitis Functional Index among patients with Ankylosing Spondylitis.开发映射算法，以根据强直性脊柱炎患者的巴斯强直性脊柱炎疾病活动指数和巴斯强直性脊柱炎功能指数预测EQ-5D健康效用值。
Health Qual Life Outcomes. 2024 Aug 7;22(1):61. doi: 10.1186/s12955-024-02276-5.
3

本文引用的文献

1
Current Development and Practice of Pharmacoeconomic Evaluation Guidelines for Universal Health Coverage in China.中国全民健康覆盖药物经济学评价指南的现状、发展与实践
Value Health Reg Issues. 2021 May;24:1-5. doi: 10.1016/j.vhri.2020.07.580. Epub 2020 Dec 19.
2
The new definition of health technology assessment: A milestone in international collaboration.新的健康技术评估定义：国际合作的里程碑。
Int J Technol Assess Health Care. 2020 Jun;36(3):187-190. doi: 10.1017/S0266462320000215. Epub 2020 May 13.
3
The Development of Health Technology Assessment in Asia: Current Status and Future Trends.
The application of multi-criteria decision analysis in evaluating the value of drug-oriented intervention: a literature review.
多标准决策分析在评估以药物为导向的干预措施价值中的应用：一项文献综述。
Front Pharmacol. 2024 Apr 24;15:1245825. doi: 10.3389/fphar.2024.1245825. eCollection 2024.
4
Mapping of health technology assessment in China: a comparative study between 2016 and 2021.中国卫生技术评估的绘制：2016 年与 2021 年的比较研究。
Glob Health Res Policy. 2024 Jan 16;9(1):4. doi: 10.1186/s41256-023-00339-6.
亚洲卫生技术评估的发展：现状与未来趋势。
Value Health Reg Issues. 2020 May;21:39-44. doi: 10.1016/j.vhri.2019.08.472. Epub 2019 Oct 18.
4
Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.死亡率、发病率和风险因素在中国及其省份，1990-2017 年：2017 年全球疾病负担研究的系统分析。
Lancet. 2019 Sep 28;394(10204):1145-1158. doi: 10.1016/S0140-6736(19)30427-1. Epub 2019 Jun 24.
5
Driving factors and mode transformation regarding health technology assessment (HTA) in China: Problems and recommendations.推动中国健康技术评估（HTA）的因素和模式转变：问题与建议。
Biosci Trends. 2019 May 12;13(2):110-116. doi: 10.5582/bst.2019.01100. Epub 2019 Apr 20.
6
Development of health technology assessment in China: New challenges.中国卫生技术评估的发展：新挑战。
Biosci Trends. 2018;12(2):102-108. doi: 10.5582/bst.2018.01038.